San Diego Union-Tribune examines pharma's growing interest in neglected diseases

The San Diego Union-Tribune examines the pharmaceutical industry's growing interest in developing new treatments for what are known as "neglected diseases."

"Using powerful genetic-analysis tools more commonly targeted to cancer and other diseases prevalent in industrialized nations, researchers are studying patterns that underlie malaria and tuberculosis in developing countries and more obscure conditions such as leishmaniasis and Chagas' disease," the newspaper writes.

"Fueled by new funding sources, such as the Bill and Melinda Gates Foundation, companies have pushed almost two dozen drugs into clinical trials," according to the San Diego Union-Tribune.

The article focuses on the pharmaceutical company Novartis' work in "finding drugs for some diseases with little or no moneymaking potential," and examines potential funding sources for drug development (Kupper, 4/11).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Evo model set to transform synthetic biology and disease diagnosis